JP2018524274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524274A5 JP2018524274A5 JP2017559093A JP2017559093A JP2018524274A5 JP 2018524274 A5 JP2018524274 A5 JP 2018524274A5 JP 2017559093 A JP2017559093 A JP 2017559093A JP 2017559093 A JP2017559093 A JP 2017559093A JP 2018524274 A5 JP2018524274 A5 JP 2018524274A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- composition
- dgla
- epa
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 206010016654 Fibrosis Diseases 0.000 claims description 21
- 230000004761 fibrosis Effects 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- JEGJFECBWADGJX-RHDCIPCHSA-N (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid Chemical compound O=C(/C=C/C=C\C\C=C/CCCCCCC(=O)O)CCCCC JEGJFECBWADGJX-RHDCIPCHSA-N 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- ZMWDTYRCKREXOK-XWJJKCKWSA-N (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid Chemical compound O=C(/C=C/C=C\C\C=C/C\C=C/CCCC(=O)O)C\C=C/CC ZMWDTYRCKREXOK-XWJJKCKWSA-N 0.000 claims description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 2
- 239000005485 Azilsartan Substances 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- 229940126692 CXCR3 antagonist Drugs 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 239000005480 Olmesartan Substances 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 102000009266 Y-Box-Binding Protein 1 Human genes 0.000 claims description 2
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000003367 anti-collagen effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 229960002731 azilsartan Drugs 0.000 claims description 2
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims description 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229940038717 copaxone Drugs 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960004563 eprosartan Drugs 0.000 claims description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
- 210000001503 joint Anatomy 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 210000001370 mediastinum Anatomy 0.000 claims description 2
- 229960005108 mepolizumab Drugs 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 229950007699 mogamulizumab Drugs 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 210000000651 myofibroblast Anatomy 0.000 claims description 2
- 230000001722 neurochemical effect Effects 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229960005117 olmesartan Drugs 0.000 claims description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- 229960004556 tenofovir Drugs 0.000 claims description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 2
- 125000005457 triglyceride group Chemical group 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160863P | 2015-05-13 | 2015-05-13 | |
| US62/160,863 | 2015-05-13 | ||
| PCT/IB2016/000732 WO2016181221A1 (en) | 2015-05-13 | 2016-05-12 | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020446A Division JP7229285B2 (ja) | 2015-05-13 | 2021-02-12 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524274A JP2018524274A (ja) | 2018-08-30 |
| JP2018524274A5 true JP2018524274A5 (enExample) | 2019-09-05 |
Family
ID=56131573
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559093A Pending JP2018524274A (ja) | 2015-05-13 | 2016-05-12 | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2021020446A Active JP7229285B2 (ja) | 2015-05-13 | 2021-02-12 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2023020423A Withdrawn JP2023065454A (ja) | 2015-05-13 | 2023-02-14 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2025002652A Pending JP2025061087A (ja) | 2015-05-13 | 2025-01-08 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020446A Active JP7229285B2 (ja) | 2015-05-13 | 2021-02-12 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2023020423A Withdrawn JP2023065454A (ja) | 2015-05-13 | 2023-02-14 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2025002652A Pending JP2025061087A (ja) | 2015-05-13 | 2025-01-08 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10047033B2 (enExample) |
| EP (1) | EP3294282A1 (enExample) |
| JP (4) | JP2018524274A (enExample) |
| CN (3) | CN107847477A (enExample) |
| HK (1) | HK1250345A1 (enExample) |
| MA (1) | MA47141A (enExample) |
| WO (1) | WO2016181221A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015185698A1 (en) | 2014-06-04 | 2015-12-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and use of same |
| JP2018524274A (ja) * | 2015-05-13 | 2018-08-30 | ディーエス バイオファーマ リミテッド | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| CN113230244A (zh) | 2015-12-18 | 2021-08-10 | 艾菲穆恩有限公司 | 包含15-hepe的组合物及其使用方法 |
| EP3866759A1 (en) * | 2018-10-18 | 2021-08-25 | DS Biopharma Limited | Dgla and/or 15-hetre for treating inflammatory, fibrotic, and proliferative conditions |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47777B1 (en) | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| JPH04507397A (ja) | 1988-01-14 | 1992-12-24 | フリッツ，アンデルス | 湿疹治療用薬剤製造における必須脂肪酸の使用法 |
| CA1334002C (en) | 1988-09-28 | 1995-01-17 | Barry D. Sears | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals |
| GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| DE4238869C2 (de) | 1992-11-18 | 1994-09-08 | Wogepharm Gmbh | Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| ATE162071T1 (de) | 1993-10-01 | 1998-01-15 | Scherer Corp R P | Zusammensetzungen zum verteilen von duftstoffen |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| IL151299A0 (en) | 2000-02-16 | 2003-04-10 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
| JP2002047176A (ja) | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| MXPA03010888A (es) | 2001-05-30 | 2004-02-27 | Laxdale Ltd | Coenzimas q y acido eicosapentaenoico (epa). |
| JP2003155233A (ja) | 2001-11-16 | 2003-05-27 | Idemitsu Technofine Co Ltd | 塗布剤 |
| KR20110053281A (ko) | 2002-11-22 | 2011-05-19 | 니폰스이산가부시키가이샤 | 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는 조성물 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| KR20070040381A (ko) | 2004-07-01 | 2007-04-16 | 셰펜스 아이 리써치 | 눈의 장애 및 상태를 치료하는 조성물 및 방법 |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| EP1852114B1 (en) | 2005-02-14 | 2019-09-18 | Suntory Holdings Limited | Composition containing dihomo-y-linolenic acid (dgla) as active ingredient |
| JP5101894B2 (ja) | 2007-01-15 | 2012-12-19 | サントリーホールディングス株式会社 | 高度不飽和脂肪酸及びこれを含有する脂質の製造方法 |
| PE20100156A1 (es) | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| JPWO2009154230A1 (ja) | 2008-06-17 | 2011-12-01 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| JP6185473B2 (ja) | 2011-09-16 | 2017-08-23 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| SG11201403805WA (en) | 2012-01-06 | 2014-08-28 | Omthera Pharmaceuticals Inc | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
| US20130267598A1 (en) * | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| WO2013150386A2 (en) | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| MX372724B (es) * | 2012-12-24 | 2020-06-19 | Qualitas Health Inc | Formulaciones de acido eicosapentaenoico (epa). |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| TWI742541B (zh) | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| CN105592846A (zh) | 2013-03-15 | 2016-05-18 | 持田制药株式会社 | 用于治疗非酒精性脂肪性肝炎的组合物和方法 |
| WO2015185698A1 (en) | 2014-06-04 | 2015-12-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and use of same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| JP2018524274A (ja) * | 2015-05-13 | 2018-08-30 | ディーエス バイオファーマ リミテッド | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| CN113230244A (zh) | 2015-12-18 | 2021-08-10 | 艾菲穆恩有限公司 | 包含15-hepe的组合物及其使用方法 |
| US20170196825A1 (en) | 2016-01-07 | 2017-07-13 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and use of same |
-
2016
- 2016-05-12 JP JP2017559093A patent/JP2018524274A/ja active Pending
- 2016-05-12 MA MA047141A patent/MA47141A/fr unknown
- 2016-05-12 WO PCT/IB2016/000732 patent/WO2016181221A1/en not_active Ceased
- 2016-05-12 EP EP16729367.9A patent/EP3294282A1/en active Pending
- 2016-05-12 CN CN201680040919.0A patent/CN107847477A/zh active Pending
- 2016-05-12 US US15/153,476 patent/US10047033B2/en active Active
- 2016-05-12 HK HK18109827.0A patent/HK1250345A1/zh unknown
- 2016-05-12 CN CN202111198132.6A patent/CN113896628A/zh active Pending
- 2016-05-12 CN CN202311320835.0A patent/CN117402059A/zh active Pending
-
2018
- 2018-03-14 US US15/921,211 patent/US10570083B2/en active Active
-
2020
- 2020-01-13 US US16/741,015 patent/US20210230094A1/en not_active Abandoned
-
2021
- 2021-02-12 JP JP2021020446A patent/JP7229285B2/ja active Active
- 2021-11-16 US US17/527,440 patent/US12017986B2/en active Active
-
2023
- 2023-02-14 JP JP2023020423A patent/JP2023065454A/ja not_active Withdrawn
-
2025
- 2025-01-08 JP JP2025002652A patent/JP2025061087A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536380A5 (enExample) | ||
| JP2018524274A5 (enExample) | ||
| JP7030656B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ－γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP7548567B2 (ja) | Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 | |
| Strazzabosco et al. | Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium | |
| CN114761018A (zh) | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 | |
| JP2021506900A (ja) | Ｃ５ａＲ阻害剤としてのジアリール置換５，５−縮合環化合物 | |
| RU2017122758A (ru) | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций | |
| JP2012021001A5 (enExample) | ||
| EP3536320A1 (en) | Application of hedgehog pathway inhibitor for treatment of fibrotic diseases | |
| JP2012505837A5 (enExample) | ||
| JP7229285B2 (ja) | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| JP2008530101A (ja) | 有機化合物の組合わせ剤 | |
| Luo et al. | Inhibition of macrophage migration inhibitory factor (MIF) as a therapeutic target in bleomycin-induced pulmonary fibrosis rats | |
| JP2017530163A5 (enExample) | ||
| JP7751597B2 (ja) | 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤 | |
| JP2017524663A (ja) | 線維性疾患の治療に用いられるｐｐａｒ化合物 | |
| WO2014190316A1 (en) | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma | |
| AU2017328999B2 (en) | Combination of FXR agonists | |
| Personnaz et al. | Macrophage‐derived HMGB1 is dispensable for tissue fibrogenesis | |
| JP2011503008A5 (enExample) | ||
| CN106714842B (zh) | 包含双重PI3K δ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物 | |
| Steiner et al. | Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart | |
| CN111511359A (zh) | 非甾体选择性糖皮质激素受体激动调节剂(segram)及其用途 | |
| WO2025134073A2 (en) | Methods and compositions for treating diseases or conditions induced by corticosteroids, synovial inflammation, and degenerative joint disease |